Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Tritonpoint Wealth LLC

Tritonpoint Wealth LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 2,486 shares of the biopharmaceutical company’s stock after selling 69 shares during the period. Tritonpoint Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $1,305,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Marietta Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after acquiring an additional 2,501 shares in the last quarter. Sepio Capital LP grew its position in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 842 shares during the period. Founders Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after buying an additional 538 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after buying an additional 814,713 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after purchasing an additional 955 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $563.90 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,070.00. The firm’s 50 day moving average is $569.79 and its 200-day moving average is $570.27. The firm has a market capitalization of $59.77 billion, a price-to-earnings ratio of 14.21, a PEG ratio of 1.80 and a beta of 0.35. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the prior year, the business earned $11.56 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on REGN. Sanford C. Bernstein lifted their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 27th. Canaccord Genuity Group restated a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a “buy” rating and a $890.00 target price for the company. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Finally, Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.